Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$91.95 USD

91.95
548,324

+0.45 (0.49%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $92.05 +0.10 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (147 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Agios Pharmaceuticals (AGIO) Soars 5.2%: Is Further Upside Left in the Stock?

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Haemonetics (HAE) Up 11% in a Year: Will the Rally Continue?

Investors are optimistic about Haemonetics (HAE) owing to its strategic focus on establishing leading positions in high-growth markets and raised guidance.

HAE or SYK: Which Is the Better Value Stock Right Now?

HAE vs. SYK: Which Stock Is the Better Value Option?

Thermo Fisher (TMO) End Markets Drive Growth Amid Macro Woes

In the academic and government end markets, Thermo Fisher (TMO) is delivering strong growth in the electron microscopy, chromatography and mass spectrometry businesses.

Here's Why You Should Retain Edward Lifesciences (EW) Stock Now

Investors remain optimistic about Edward Lifesciences (EW) due to the strength of its product group.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic's (MDT) expansion in global markets and stable solvency position.

Omnicell (OMCL) Gains From Innovation Amid Cost Pressure

Omnicell (OMCL) plans to focus on integrating customer success functions into its broader organizational structure.

Here's Why You Should Retain Teleflex (TFX) Stock for Now

Investors remain optimistic about Teleflex (TFX), backed by the strong prospects of the Interventional business and stable solvency.

Boston Scientific (BSX) Initiates AVANT GUARD Clinical Trial

Boston Scientific's (BSX) AVANT GUARD clinical trial is set to evaluate the FARAPULSE PFA System as the first-line treatment for persistent AF.

Here's Why Haemonetics (HAE) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Globus Medical (GMED) Gains From Innovation Amid Macro Issues

Globus Medical (GMED) is particularly seeing notable gains in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

Investors remain optimistic about Labcorp (LH) due to impressive partnerships and expansion efforts in targeted high-growth areas.

Moumi Mondal headshot

5 Impressive MedTech Industry Growth Stocks to Buy for 2024

Stocks such as HAE, PEN, EXAS, PODD and CAH are set to garner remarkable growth for investors.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

Investors are optimistic about Insulet (PODD), led by the strong adoption of Omnipod 5 and its strong solvency position.

Here's Why You Should Retain Illumina (ILMN) Stock for Now

Investors are optimistic about Illumina's (ILMN) strength in the genomics market and strong solvency position.

National Vision (EYE) Store Openings Aid, Macro Issues Stay

In terms of store expansion, National Vision (EYE) continues to see sizable new opportunities for many years to come.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.

Reasons to Buy Prestige Consumer (PBH) Stock for Now

Investors remain optimistic about Prestige Consumer (PBH), backed by the robust strength of its consumer brands portfolio.

Align Technology (ALGN) Up 30% YTD: Will the Rally Continue?

Investors are optimistic about Align Technology (ALGN), driven by recent strategic alliance and geographic expansion.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Henry Schein (HSIC) Sales Hurt by Cyber Attack, Macro Woes

Henry Schein's (HSIC) financial operations are being affected by the current macroeconomic environment.

Orthofix (OFIX) Releases New Data for Spinal Fusion Procedures

According to Orthofix (OFIX), this data highlights the noninvasive and cost-effective nature of SpinalStim, enabling patients to continue their healing in the comfort of their homes.

Here's Why Investors Should Retain Bruker (BRKR) Stock Now

Investors remain optimistic about Bruker (BRKR) due to the strength of the BSI BioSpin and CALID groups.

5 MedTech Stocks Poised to Continue Their Winning Streaks in 2024

Stocks like DexCom Inc. (DXCM), Integer Holdings (ITGR), Penumbra (PEN), Haemonetics (HAE), Health Equity (HAE) and are likely to continue their strong performance in 2024.

Thermo Fisher (TMO) Unveils CorEvitas Pharmacovigilance Platform

Thermo Fisher (TMO) introduces the CorEvitas pharmacovigilance platform for clinical research registries.